The device has not been returned/received to date.If the device is received, a supplemental report will be submitted with the investigation results.It was reported that the cannula had dislodged from the infusion site.This condition could interrupt insulin delivery and contribute to hyperglycemia.Lot release records were reviewed and the product lot met all acceptance criteria.Specifically, a pod is paired to a pdm and put through simulated use testing including communicating with the pdm, deployment, delivering fluid, occlusion detection, and freedom from hazard alarms.
|
It was reported the patient's blood glucose level (bg) read "high" (>27.8 mmol/l,>500 mg/dl) with ketones of 4.6 mmol/l while wearing the pod between 24 and 36 hours.Symptoms reported include fatigue, abdominal pain and confusion.The pod reportedly fell off the infusion site (leg), causing the cannula to dislodge.As treatment, a new pod was applied and the patient drank lots of fluids.
|